263 related articles for article (PubMed ID: 8438453)
1. Effect of rapamycin on induction of unresponsiveness in ALS-treated, marrow-injected mice.
Bobbio SA; Wood ML; Monaco AP
Transplant Proc; 1993 Feb; 25(1 Pt 1):717-8. PubMed ID: 8438453
[No Abstract] [Full Text] [Related]
2. Extended skin allo- and xenograft survival in mice treated with rapamycin, antilymphocyte serum, and donor-specific bone marrow transfusion.
Hale DA; Gottschalk R; Fukuzaki T; Wood ML; Maki T; Monaco AP
Transplant Proc; 1996 Dec; 28(6):3269. PubMed ID: 8962269
[No Abstract] [Full Text] [Related]
3. Induction of tolerance to skin allografts by intrathymic injection of donor splenocytes. Effect of donor-recipient strain combination and supplemental rapamycin.
Dono K; Maki T; Wood ML; Monaco AP
Transplantation; 1995 Dec; 60(11):1268-73. PubMed ID: 8525521
[TBL] [Abstract][Full Text] [Related]
4. Effect of rapamycin on islet and skin xenograft survival.
Bobbio SA; Porter JG; Monaco AP
Transplant Proc; 1993 Aug; 25(4):2745-6. PubMed ID: 8356733
[No Abstract] [Full Text] [Related]
5. Effect of single-dose, late treatment with rapamycin on skin allograft survival in ALS- and donor bone marrow cell-treated mice.
De Fazio SR; Plowey J; Hartner WC; Gozzo JJ
Transplant Proc; 1994 Dec; 26(6):3102-3. PubMed ID: 7998084
[No Abstract] [Full Text] [Related]
6. Determination of an improved sirolimus (rapamycin)-based regimen for induction of allograft tolerance in mice treated with antilymphocyte serum and donor-specific bone marrow.
Hale DA; Gottschalk R; Maki T; Monaco AP
Transplantation; 1998 Feb; 65(4):473-9. PubMed ID: 9500619
[TBL] [Abstract][Full Text] [Related]
7. Suppression of allograft responses by combining alloantigen-specific i.v. presensitization with suboptimal doses of FK 506 or rapamycin.
Iwata H; Nagano T; Toyo-oka K; Hirose H; Hamaoka T; Fujiwara H
Transplant Proc; 1994 Apr; 26(2):851-4. PubMed ID: 7513476
[No Abstract] [Full Text] [Related]
8. Augmentation by donor bone marrow of the survival of neonatal skin transplants to ALS-treated recipients.
Gozzo JJ; Kowolenko M
Transplant Proc; 1987 Feb; 19(1 Pt 1):470-1. PubMed ID: 3274809
[No Abstract] [Full Text] [Related]
9. Synergistic effect of immunosuppressive drug and intrathymic inoculation of donor cells in skin graft survival.
Dono K; Wood ML; Ozato H; Monaco AP
Transplant Proc; 1994 Oct; 26(5):3061. PubMed ID: 7940963
[No Abstract] [Full Text] [Related]
10. Use of pharmacologic immunosuppression to augment the specific unresponsiveness (tolerance) to skin allografts induced by donor-specific bone marrow in antilymphocyte serum-treated mice: the unique effect of sirolimus.
Hale D; Gottschalk R; Maki T; Monaco AP
Transplant Proc; 1998 Aug; 30(5):2432-4. PubMed ID: 9723527
[TBL] [Abstract][Full Text] [Related]
11. Indefinite survival of skin allografts in adult thymectomized, antilymphocyte serum-treated mice given bone marrow and thymus grafts of donor origin: tolerance induction by donor bone marrow and thymus.
Fukuzaki T; Hancock WW; Monaco AP; Maki T
Transplantation; 1998 Apr; 65(8):1036-43. PubMed ID: 9583862
[TBL] [Abstract][Full Text] [Related]
12. Importance of schedule of administration of adjunctive, short-term immunosuppression in ALS- and bone marrow cell-treated, skin-allografted mice.
Gozzo JJ; Plowey J; Hartner WC; De Fazio SR
Transplant Proc; 1995 Feb; 27(1):169-70. PubMed ID: 7878958
[No Abstract] [Full Text] [Related]
13. Models of specific unresponsiveness to tissue allografts in antilymphocyte serum (ALS) treated mice.
Wood ML; Monaco AP
Transplant Proc; 1978 Jun; 10(2):379-87. PubMed ID: 354127
[No Abstract] [Full Text] [Related]
14. Superiority of sirolimus (rapamycin) over cyclosporine in augmenting allograft and xenograft survival in mice treated with antilymphocyte serum and donor-specific bone marrow.
Hale DA; Gottschalk R; Fukuzaki T; Wood ML; Maki T; Monaco AP
Transplantation; 1997 Feb; 63(3):359-64. PubMed ID: 9039923
[TBL] [Abstract][Full Text] [Related]
15. Effect of posttransplant injection of peripheral blood lymphocytes on skin graft prolongation in mice treated with antilymphocyte serum (ALS) or ALS plus donor bone marrow.
Gozzo JJ; Hartner WC; Monaco AP; De Fazio SR
Transplant Proc; 1987 Feb; 19(1 Pt 2):1409-10. PubMed ID: 3274341
[No Abstract] [Full Text] [Related]
16. Bone marrow cells that prolong graft survival in ALS-treated mice: suppressor activity in mixed cell culture.
De Fazio SR; Monaco AP; Gozzo JJ
Transplant Proc; 1989 Feb; 21(1 Pt 1):228-30. PubMed ID: 2523127
[No Abstract] [Full Text] [Related]
17. Inhibition of skin graft rejection in mice by rapamycin: a novel immunosuppressive macrolide.
Eng CP; Gullo-Brown J; Chang JY; Sehgal SN
Transplant Proc; 1991 Feb; 23(1 Pt 1):868-9. PubMed ID: 1990708
[No Abstract] [Full Text] [Related]
18. Bromocriptine prevents the immunosuppression induced in mice by anti-lymphocytic antiserum.
Rosso di San Secondo VE; Fitch C; Aniasi A; Close FT; Sirchia G; Freeman ME
Transplant Proc; 1996 Dec; 28(6):3193-5. PubMed ID: 8962238
[No Abstract] [Full Text] [Related]
19. Tolerance induction to skin allografts following intrathymic injection with donor-specific splenocytes in major histocompatibility complex class I, class I+MLS, and class I+II disparities.
Ohzato H; Monaco AP
Transplant Proc; 1993 Feb; 25(1 Pt 1):297-8. PubMed ID: 8438307
[No Abstract] [Full Text] [Related]
20. Specificity requirement of donor bone marrow cells that prolong allograft survival: implications for a veto cell mechanism of action.
De Fazio SR; Markees TG; Hartner WC; Gozzo JJ
Transplant Proc; 1995 Feb; 27(1):171-3. PubMed ID: 7878960
[No Abstract] [Full Text] [Related]
[Next] [New Search]
